Malaria Information and Prophylaxis, by Country [T]
|Country||Areas with Malaria||Drug Resistance2||Malaria Species3||Recommended Chemoprophylaxis4||Key Information Needed and Helpful Links to Assess Need for Prophylaxis for Select Countries|
|Taiwan||None||Not Applicable||Not Applicable||Not Applicable|
|Tajikistan||No indigenous cases reported since 2014.||Previously, chloroquine||Previously, P. vivax 90% and
P. falciparum 10%
|None (mosquito avoidance only).6|
|Tanzania||All areas at altitudes < 1,800 m (5,906 ft)||Chloroquine||Primarily P. falciparum. Less commonly, P. malariae or P. ovale;
P. vivax rare
|Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5||Altitude of city(ies) of travel|
|Thailand||Primarily in provinces that border Burma (Myanmar), Cambodia (few cases in Buriram), and Malaysia (few cases in Satun), and the provinces of Surat Thani, Ubon Ratchathani, and Phitsanulok, especially the rural forest and forest fringe areas of these provinces. Rare to few cases in other parts of Thailand, including the cities of Bangkok, Chiang Mai, and Chiang Rai, and the islands of Koh Phangan, Koh Samui, and Phuket. None in the islands of Krabi Province (Koh Phi Phi, Koh Yao Noi, Koh Yao Yai, and Ko Lanta) and Pattaya City||Chloroquine and Mefloquine||P. vivax 80%; P. falciparum <20%; P. knowlesi,7 P. malariae and P. ovale rare.
|Provinces that border Burma (Myanmar), Cambodia (except Buriram), and Malaysia (except Satun), and the provinces of Surat Thani, Ubon Ratchathani, and Phitsanulok:
Atovaquone-proguanil doxycycline, or tafenoquine5.
Other areas with malaria:
|Map of provinces of Thailand to determine if a city is within a certain districtexternal icon|
|Timor-Leste (East Timor)||Rare cases; outbreak in Indonesia border area in mid-2020.||Chloroquine||Previously, P. falciparum 50%,
P. vivax 50%,
P. ovale <1%,
P. malariae <1%
|None (mosquito avoidance only).6|
|Togo||All||Chloroquine||Primarily P. falciparum. Less commonly, P. malariae, P. ovale, or P. vivax.||Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5|
|Tokelau (New Zealand)||None||Not Applicable||Not Applicable||Not Applicable|
|Tonga||None||Not Applicable||Not Applicable||Not Applicable|
|Trinidad and Tobago||None||Not Applicable||Not Applicable||Not Applicable|
|Tunisia||None||Not Applicable||Not Applicable||Not Applicable|
|Turkey||None||Not Applicable||Not Applicable||Not Applicable|
|Turkmenistan||None||Not Applicable||Not Applicable||Not Applicable|
|Turks and Caicos Islands (U.K.)||None||Not Applicable||Not Applicable||Not Applicable|
|Tuvalu||None||Not Applicable||Not Applicable||Not Applicable|
1. Factors that affect local malaria transmission patterns can change rapidly and from year to year, such as local weather conditions, mosquito vector density, and prevalence of infection. Information in these tables is updated regularly.
2. Refers to P. falciparum malaria unless otherwise noted.
3. Estimates of malaria species are based on best available data from multiple sources. Where proportions are not available, the primary species and less common species are identified.
4. Several medications are available for chemoprophylaxis. When deciding which drug to use, consider specific itinerary, length of trip, cost of drug, previous adverse reactions to antimalarials, drug allergies, and current medical history. All travelers should seek medical attention in the event of fever during or after return from travel to areas with malaria.
5. Primaquine and tafenoquine can cause hemolytic anemia in persons with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Before prescribing primaquine or tafenoquine, patients must be screened for G6PD deficiency using a quantitative test.
6. Mosquito avoidance includes applying topical mosquito repellant, sleeping under an insecticide treated bed net, and wearing protective clothing (e.g., long pants and socks, long sleeve shirt). For additional details on mosquito avoidance, see: https://www.cdc.gov/malaria/travelers/index.html
7. P. knowlesi is a malaria species with a simian host (macaque). Human cases have been reported from most countries in Southeast Asia and are associated with activities in forest or forest-fringe areas. This species of malaria has no known resistance to antimalarials.